Immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia
Background/Aim. Prostate carcinoma (PCa) and its parent organ are influenced by hormones, which is used for therapeutic purposes. Through androgen receptors (AR) androgens influence cell growth and function, proliferation, differentiation, apoptosis, lipid metabolism and secretory activity of the pr...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade
2020-01-01
|
| Series: | Vojnosanitetski Pregled |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0042-8450/2020/0042-84501800083T.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850237293852360704 |
|---|---|
| author | Trivunić-Dajko Sandra Bogdanović Jovo Fejsa-Levakov Aleksandra Živojinov Mirjana Đolai Matilda |
| author_facet | Trivunić-Dajko Sandra Bogdanović Jovo Fejsa-Levakov Aleksandra Živojinov Mirjana Đolai Matilda |
| author_sort | Trivunić-Dajko Sandra |
| collection | DOAJ |
| description | Background/Aim. Prostate carcinoma (PCa) and its parent organ are influenced by hormones, which is used for therapeutic purposes. Through androgen receptors (AR) androgens influence cell growth and function, proliferation, differentiation, apoptosis, lipid metabolism and secretory activity of the prostate, as well as development and progression of PCa. An antiandrogen therapy is carried out in patients with metastatic PCa, in order to block effects of androgens. By conducting immunohistochemical analysis of androgen receptors in the PCa tissue, we can assume how the tumour will react to an administered antiandrogen therapy, both in androgen-positive and androgen-negative, resistant tumours. Knowledge of the presence of AR in the tumour tissue may serve as a prognostic indicator in histopathological analysis. The aim of this study was to evaluate the expression of AR in patients with benign prostatic hyperplasia (BPH) and in those with PCa, before therapy. Methods. Immunohistochemical analysis was carried out by using anti-human AR monoclonal antibody AR441 (DAKO), and presence and intensity of AR were semi-quantitatively evaluated in 195 patients, 165 with BPH and 30 with PCa. Material for analysis was obtained by needle biopsy or transurethral resection of the prostate (TURP). Results. All secretory cells in patients with BPH were intensively androgen positive, while in patients with PCa they were mostly moderately to highly positive, but with foci of negativity. The observed negative correlation between AR and Gleason score and the International Society of Urologic Pathology (ISUP) grade group of PCa was not statistically significant. Conclusion. Study results indicate that PCa, before therapy, is androgen-dependent, with a high level of AR expression. |
| format | Article |
| id | doaj-art-3518c55facc542f2aebddf823583af4b |
| institution | OA Journals |
| issn | 0042-8450 2406-0720 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade |
| record_format | Article |
| series | Vojnosanitetski Pregled |
| spelling | doaj-art-3518c55facc542f2aebddf823583af4b2025-08-20T02:01:46ZengMinistry of Defence of the Republic of Serbia, University of Defence, BelgradeVojnosanitetski Pregled0042-84502406-07202020-01-0177442643010.2298/VSP170629083T0042-84501800083TImmunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasiaTrivunić-Dajko Sandra0Bogdanović Jovo1Fejsa-Levakov Aleksandra2Živojinov Mirjana3Đolai Matilda4University of Novi Sad, Faculty of Medicine, Department of Pathology, Novi Sad, Serbia + Clinical Centre of Vojvodina, Centre for Pathology and Histology, Novi Sad, SerbiaUniversity of Novi Sad, Department of surgery, Novi Sad, Serbia + Clinical Centre of Vojvodina, Clinic of Urology, Novi Sad, SerbiaClinical Centre of Vojvodina, Centre for Pathology and Histology, Novi Sad, Serbia + University of Novi Sad, Department of Histology and Embriology, Novi Sad, SerbiaUniversity of Novi Sad, Faculty of Medicine, Department of Pathology, Novi Sad, Serbia + Clinical Centre of Vojvodina, Centre for Pathology and Histology, Novi Sad, SerbiaClinical Centre of Vojvodina, Centre for Pathology and Histology, Novi Sad, Serbia + University of Novi Sad, Department of Histology and Embriology, Novi Sad, SerbiaBackground/Aim. Prostate carcinoma (PCa) and its parent organ are influenced by hormones, which is used for therapeutic purposes. Through androgen receptors (AR) androgens influence cell growth and function, proliferation, differentiation, apoptosis, lipid metabolism and secretory activity of the prostate, as well as development and progression of PCa. An antiandrogen therapy is carried out in patients with metastatic PCa, in order to block effects of androgens. By conducting immunohistochemical analysis of androgen receptors in the PCa tissue, we can assume how the tumour will react to an administered antiandrogen therapy, both in androgen-positive and androgen-negative, resistant tumours. Knowledge of the presence of AR in the tumour tissue may serve as a prognostic indicator in histopathological analysis. The aim of this study was to evaluate the expression of AR in patients with benign prostatic hyperplasia (BPH) and in those with PCa, before therapy. Methods. Immunohistochemical analysis was carried out by using anti-human AR monoclonal antibody AR441 (DAKO), and presence and intensity of AR were semi-quantitatively evaluated in 195 patients, 165 with BPH and 30 with PCa. Material for analysis was obtained by needle biopsy or transurethral resection of the prostate (TURP). Results. All secretory cells in patients with BPH were intensively androgen positive, while in patients with PCa they were mostly moderately to highly positive, but with foci of negativity. The observed negative correlation between AR and Gleason score and the International Society of Urologic Pathology (ISUP) grade group of PCa was not statistically significant. Conclusion. Study results indicate that PCa, before therapy, is androgen-dependent, with a high level of AR expression.http://www.doiserbia.nb.rs/img/doi/0042-8450/2020/0042-84501800083T.pdfprostate neoplasmsreceptors, androgenprostatic hyperplasiaimmunohistochemistry |
| spellingShingle | Trivunić-Dajko Sandra Bogdanović Jovo Fejsa-Levakov Aleksandra Živojinov Mirjana Đolai Matilda Immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia Vojnosanitetski Pregled prostate neoplasms receptors, androgen prostatic hyperplasia immunohistochemistry |
| title | Immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia |
| title_full | Immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia |
| title_fullStr | Immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia |
| title_full_unstemmed | Immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia |
| title_short | Immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia |
| title_sort | immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia |
| topic | prostate neoplasms receptors, androgen prostatic hyperplasia immunohistochemistry |
| url | http://www.doiserbia.nb.rs/img/doi/0042-8450/2020/0042-84501800083T.pdf |
| work_keys_str_mv | AT trivunicdajkosandra immunohistochemicalexpressionofandrogenreceptorsinprostatecarcinomaandbenignprostatichyperplasia AT bogdanovicjovo immunohistochemicalexpressionofandrogenreceptorsinprostatecarcinomaandbenignprostatichyperplasia AT fejsalevakovaleksandra immunohistochemicalexpressionofandrogenreceptorsinprostatecarcinomaandbenignprostatichyperplasia AT zivojinovmirjana immunohistochemicalexpressionofandrogenreceptorsinprostatecarcinomaandbenignprostatichyperplasia AT đolaimatilda immunohistochemicalexpressionofandrogenreceptorsinprostatecarcinomaandbenignprostatichyperplasia |